Phase 1/2a Study of the Safety and Bioactivity of AXT-107 in Subjects With Diabetic Macular Edema (DME)
Latest Information Update: 27 Mar 2024
At a glance
- Drugs Gersizangitide (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Acronyms CONGO
- Sponsors AsclepiX Therapeutics
Most Recent Events
- 20 Mar 2024 Status changed from completed to discontinued.
- 16 Nov 2022 Status changed from active, no longer recruiting to completed.
- 19 Jul 2022 Planned End Date changed from 1 Jul 2022 to 1 Oct 2022.